Insurance rejections, high copayments, physician perception of high risk, and African Americans’ lack of trust in the healthcare system all played a colossal part in the discrepancy in using statins or PCSK9 inhibitors to treat hyperlipidemia. The gene discussed is PCSK9; the disease is hyperlipidemia.